207 related articles for article (PubMed ID: 12436824)
1. The COX-2 inhibitors: new analgesic and anti-inflammatory drugs.
Khan AA; Dionne RA
Dent Clin North Am; 2002 Oct; 46(4):679-90. PubMed ID: 12436824
[TBL] [Abstract][Full Text] [Related]
2. COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery.
Cicconetti A; Bartoli A; Ripari F; Ripari A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Feb; 97(2):139-46. PubMed ID: 14970772
[TBL] [Abstract][Full Text] [Related]
3. Selecting new drugs for pain control: evidence-based decisions or clinical impressions?
Jeske AH
J Am Dent Assoc; 2002 Aug; 133(8):1052-6; quiz 1093-4. PubMed ID: 12198983
[TBL] [Abstract][Full Text] [Related]
4. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.
Stephens J; Laskin B; Pashos C; Peña B; Wong J
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii40-52. PubMed ID: 14585917
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
Moore PA; Hersh EV
J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 enzyme inhibitors: place in therapy.
Noble SL; King DS; Olutade JI
Am Fam Physician; 2000 Jun; 61(12):3669-76. PubMed ID: 10892637
[TBL] [Abstract][Full Text] [Related]
7. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitors: new drugs for the management of pain and inflammation.
Hutchins V; Hutchins B
Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
[No Abstract] [Full Text] [Related]
9. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
[TBL] [Abstract][Full Text] [Related]
10. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
11. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control.
Chen LC; Elliott RA; Ashcroft DM
J Clin Pharm Ther; 2004 Jun; 29(3):215-29. PubMed ID: 15153083
[TBL] [Abstract][Full Text] [Related]
12. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
Fendrick AM
Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296
[TBL] [Abstract][Full Text] [Related]
13. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
15. [The coxibs, third generation anti-inflammatories].
Sternon J
Rev Med Brux; 2001 Apr; 22(2):100-5. PubMed ID: 11388024
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of cyclooxygenase-2-specific inhibitors.
Cannon GW; Breedveld FC
Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Peura DA
Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
[TBL] [Abstract][Full Text] [Related]
20. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]